Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig J Thomas

Showing results (181-190 of 227) with videos related to

Pageof 23
Sort By:
Cancer Research Communications|July 24, 2025
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC ModelsBenjamin C Brim, Andres F Leon, Erica L Beatson, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2016
Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synucleinWei Wang, Linh T T Nguyen, Christopher Burlak, et al.
Nature|May 5, 2016
NMDAR inhibition-independent antidepressant actions of ketamine metabolitesPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Cancer Research Communications|March 7, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine XenograftsYasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, et al.
Cancer Cell|May 3, 2024
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomasJaewoo Choi, Michele Ceribelli, James D Phelan, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2023
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibYing Pang, Qi Li, Zach Sergi, et al.
Cell Reports. Medicine|October 20, 2023
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanomaNadia Arang, Simone Lubrano, Michele Ceribelli, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2019
Antidepressant-relevant concentrations of the ketamine metabolite (2<i>R</i>,6<i>R</i>)-hydroxynorketamine do not block NMDA receptor functionEric W Lumsden, Timothy A Troppoli, Scott J Myers, et al.
Iscience|April 17, 2025
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibYing Pang, Qi Li, Zach Sergi, et al.
Pageof 23

Showing results (181-190 of 227) with videos related to

Sort By:
Pageof 23
Cancer Research Communications|July 24, 2025
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC ModelsBenjamin C Brim, Andres F Leon, Erica L Beatson, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2016
Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synucleinWei Wang, Linh T T Nguyen, Christopher Burlak, et al.
Nature|May 5, 2016
NMDAR inhibition-independent antidepressant actions of ketamine metabolitesPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Cancer Research Communications|March 7, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine XenograftsYasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, et al.
Cancer Cell|May 3, 2024
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomasJaewoo Choi, Michele Ceribelli, James D Phelan, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2023
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibYing Pang, Qi Li, Zach Sergi, et al.
Cell Reports. Medicine|October 20, 2023
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanomaNadia Arang, Simone Lubrano, Michele Ceribelli, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2019
Antidepressant-relevant concentrations of the ketamine metabolite (2<i>R</i>,6<i>R</i>)-hydroxynorketamine do not block NMDA receptor functionEric W Lumsden, Timothy A Troppoli, Scott J Myers, et al.
Iscience|April 17, 2025
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibYing Pang, Qi Li, Zach Sergi, et al.
Pageof 23